Science | 06 January 2025 | News
IIT Guwahati advances cholesterol and triglyceride detection with advanced nanotechnology
Researchers at Indian Institute of Technology Guwahati (IIT-G), led by Prof. Dipankar Bandyopad...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 07 January 2025 | News
Zoplar secures $3.4 M to revolutionise medical equipment accessibility
Gurugram-based startup Zoplar, an innovative platform dedicated to enhancing the medical equipment procurement...Read more
West Bengal | 08 January 2025 | News
Global Cloud Cayr launches health management services in Kolkata
Global Cloud Cayr (GCC), an innovative healthcare startup founded by an international team of doctors and...Read more
Supplier | 08 January 2025 | News
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the m...Read more
People | 18 December 2024 | News
Health tech startup Zyla Health on-boards Rohit Boda as Advisor
Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry lead...Read more
Uttar Pradesh | 08 January 2025 | News
Chandigarh University announces establishment of AI-enabled futuristic campus in Lucknow
Chandigarh University (CU) has announced the establishment of the first-of-its-kind A...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com